“The situation
of vaccination against shingles is perfectly representative of the total neglect of France in terms of vaccination !,
protests P Gaëtan Gavazzi, infectious disease specialist and professor of geriatrics at Grenoble University Hospital.
Less than 1% of the population targeted by this vaccine actually received it: what is the recommendation for? "
In 2015, the HAS issued an opinion recognizing minor therapeutic progress in the shingles vaccine for the prevention of shingles and postzosteric pain.
The injection is possible for everyone from the age of 50, but recommended between 65 and 74, the only age group for which it is reimbursed by Medicare, up to 35%.
Read also
Medical cannabis: the details and the challenges of a long-awaited experiment
"The effectiveness of a vaccine depends on the correctness of its recommendation, on an information campaign to ensure its dissemination and, above all, on a monitoring tool to monitor its use and effectiveness on the pathology targeted
," emphasizes Prof. Gavazzi.
In France, there was no awareness campaign ...
This article is for subscribers only.
You have 70% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in